Shares of AbbVie (NYSE:ABBV) saw an erosion of -0.9 points in recent session. During the trading, the value of each share was $60, dropping -1.48%. The shares saw high fund-flow as the composite value of all the upticks was $131.57 million and the total value of all the downticks was a mere $60.2 million. The net money flow was seen at $71.37 million and the up/down ratio was measured at 2.19. On a weekly basis the shares of the shares have recorded a change of -1.64%.The block trade which occurred today had $73.19 million in upticks and $1.5 million in downticks with the up/down ratio climbing to 48.71. $71.69 million was the net money flow of the block transaction.
AbbVie Inc. has lost 1.62% in the last five trading days and dropped 0.74% in the last 4 weeks. AbbVie Inc. is up 7.1% in the last 3-month period. Year-to-Date the stock performance stands at 3.35%.
Currently the company Insiders own 0.11% of AbbVie shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.87% . Institutional Investors own 66.78% of AbbVie shares. During last six month period, the net percent change held by insiders has seen a change of -14.58%. . On the companys insider trading activities, The Securities and Exchange Commission has divulged that Gonzalez Richard A, director officer (Chairman of the Board and CEO) of Abbvie Inc., had unloaded 285,953 shares at an average price of $63.87 in a transaction dated on June 2, 2016. The total value of the transaction was worth $18,263,818.
AbbVie (NYSE:ABBV) witnessed a decline in the market cap on Friday as its shares dropped 1.46% or 0.89 points. After the session commenced at $60.88, the stock reached the higher end at $60.97 while it hit a low of $59.57. With the volume soaring to 12,574,723 shares, the last trade was called at $60.01. The company has a 52-week high of $71.6. The company has a market cap of $97,058 million and there are 1,617,358,600 shares in outstanding. The 52-week low of the share price is $45.45.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.